June 2013 in “Clinical Neurophysiology” Finasteride improved reflexes and motor activity in rats with liver-related brain issues.
7 citations
,
October 2020 in “Wiener medizinische Wochenschrift” THA is a rare condition with no significant clinical consequences if thyroid function is normal.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.
7 citations
,
July 2019 in “Asian Journal of Oncology” Guduchi and Yashtimadhu can reduce chemotherapy side effects.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
17 citations
,
December 2013 in “Dermatologic Surgery” The treatment improved hair color in most vitiligo patients without major side effects.
May 2024 in “Archives of Dermatological Research” TAT-GILZ peptide promotes hair growth by boosting stem cell activity.
2 citations
,
January 2023 in “Skin Appendage Disorders” More research is needed to confirm initial findings on hair loss patterns from chemotherapy.
2 citations
,
June 1985 in “PubMed” Ethylenthiourea is toxic to the liver and nervous system, especially with alcohol.
June 2026 in “Journal of health economics and outcomes research” The study conducted a cost-per-responder analysis comparing ritlecitinib and baricitinib for treating severe alopecia areata. Ritlecitinib, a JAK3/TEC inhibitor, showed greater efficacy and a lower cost per responder than baricitinib, a JAK1/2 inhibitor, at both Weeks 24 and 52. Specifically, 52.10% of ritlecitinib initiators achieved a significant response by Week 24 compared to 36.28% for baricitinib. By Week 52, 40.26% of ritlecitinib users reached the desired outcome versus 30.63% for baricitinib. The cost per responder was lower for ritlecitinib at both time points, suggesting it may be a more cost-effective option for inclusion in treatment plans for severe alopecia areata.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
April 2006 in “Pediatrics in Review” Graves disease is the main cause of hyperthyroidism in kids, especially girls aged 11-15, and requires lifelong follow-up.
215 citations
,
November 2000 in “Journal of Investigative Dermatology” The system allows precise control of gene expression in mouse skin, useful for studying skin biology.
17 citations
,
January 2019 in “Journal of cancer” The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
6 citations
,
August 1989 in “European journal of pediatrics” Child with rickets improved with a specific vitamin D therapy, but alopecia did not change.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
46 citations
,
September 2013 in “PLOS ONE” Thyrotropin-Releasing Hormone helps heal wounds in frog and human skin.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
33 citations
,
August 1993 in “FEBS Letters” A new enzyme in rats may help regulate hair growth.
14 citations
,
August 2009 in “Cancer epidemiology” AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.
15 citations
,
June 2015 in “PLoS ONE” Thymosin beta-4 promotes hair growth in mice.
January 2016 in “Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)” FDG PET/CT can improve cancer treatment plans in dogs.
4 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings”